Covered Call Analyzer Aggressive "STOCKS-TO-CONSIDER"
|
Company Name |
Stock Symbol |
Stock Price |
# of shares |
Total Cost* |
Option Symbol |
Dec Option Price |
Income from sale* |
Strike Price |
Projected return if Called after one month* |
Actual $ return* |
Actual % Return* |
| Enzon Pharma. | ENZN | $14.79 | 600 | $8,894 | QYZLW | $0.90 | $520 | 17.5 | 29% | ($700) | -8% |
| Comments: |
Not called. Sold Jan17.5 at 0.30. Not called. Sold all shares at $12.49 to close out position. |
||||||||||
| Nectar Theraputics | NKTR | $15.09 | 600 | $9,074 | QNXLW | $0.75 | $430 | 17.5 | 25% | +$1,856 | +20% |
| Comments: |
Called. |
||||||||||
| Cyberonics, Inc. | CYBX | $19.99 | 400 | $8,016 | QAJLX | $0.90 | $340 | 22.5 | 20% | +$2,024 | +25% |
| Comments: |
Not called. Sold Jan22.5 at 1.80. Called. |
||||||||||
| Netflix, Inc. | NFLX | $11.24 | 800 | $9,012 | QNQLS | $0.55 | $420 | 12.5 | 19% | +$1,408 | +16% |
| Comments: |
Called. |
||||||||||
| Rambus, Inc. | RMBS | $20.73 | 400 | $8,312 | BNQLX | $1.05 | $400 | 22.5 | 16% | +$1,088 | +13% |
| Comments: |
Called. |
||||||||||
| Omnivision Tech. | OVTI | $18.26 | 500 | $9,150 | UCMLD | $0.70 | $330 | 20 | 16% | ($755) | -8% |
| Comments: |
Not called. Sold Jan20 at 0.35. Not called. Sold all shares at $15.78 to close out position. |
||||||||||
| Ask Jeeves, Inc. | ASKJ | $23.75 | 400 | $9,520 | AUKLS | $1.30 | $500 | 25 | 12% | +$980 | +10% |
| Comments: |
Called. |
||||||||||
| Interdigital Comm. | IDCC | $19.17 | 500 | $9,605 | DAQLD | $1.05 | $505 | 20 | 11% | +$900 | +9% |
| Comments: |
Called. |
||||||||||
| American Pharma. | APPX | $29.08 | 300 | $8,744 | AQOLF | $1.70 | $490 | 30 | 10% | +$746 | +9% |
| Comments: |
Called. |
||||||||||
| Celgene Corp. | CELG | $26.80 | 300 | $8,060 | LQHLY | $1.35 | $385 | 27.5 | 9% | +$746 | +11% |
| Comments: |
Not called. Sold Jan27.5 at 1.20. Called. |
||||||||||
|
All positions closed out with portfolio value up +$8,463. |
|||||||||||
*After the effect of all commissions.
The stocks listed above are for illustrative and educational purposes only and should not be construed as an endorsement, recommendation, or solicitation to buy or sell any particular security.